20 May 2003
The impact of obesity and liver steatosis on the rate of liver fibrosis among patients with chronic hepatitis C
W. Kryczka, M. Chrapek, K. Paluch, D. Zarębska-Michaluk, A. UrbaniakMed Sci Monit 2003; 9(2): 9-0 :: ID: 15235
Abstract
Background:To study the potential predictive role of obesity and liver steatosis (LS)on the rate of liver fibrosis (RLF)among patients with chronic hepatitis C (CHC).Material/Methods:354 consecutive,biopsy proven (assessed according to Ishak ’s criteria)patients (mean age at biopsy: 42 ±14 years;F/M:178/176)with untreated CHC and known probable duration of HCV infection were seen.Subject with other forms of liver disease as well as heavy drinkers were excluded from analysis.The RLF was defined as the ratio between fibrosis stage (scored 0 –6 units with 6 representing cirrhosis)and the duration of infection (in years). Based on published data,a patient with RLF>/=0,3 (cirrhosis up to 20 years after HCV infection)was considered as rapid progressor. The obesity was defined as body mass index >30 kg/m 2 .In our analysis,the LS was graded as 0,1,2 respectively to less than 1% (or absence),1 –10%and more than 10%hepatocytes involved. Results: Overall, 15% (54/354)patients were rapid progressors. 13%(46/354)patients were obese and the grade 0,1 and 2 of LS was observed in 58% (201/354), 34%(121/354) and 9% (32/354)of patients, respectively.The rapid progressors were significantly more frequently noted among obese than among non-obese patients (30%vs.13%;p=0,004)as well as among patients with increasing LS (12%,17%and 28%rapid progressors,respectively among patients with grade 0,1 and 2 of LS; p=0.04).In logistic regression analysis,after adjusting for age at biopsy and sex,only obesity (adjusted OR=2,2; 95%CI [1.1 –4.7 ];p=0.03)and not LS (p=0.21)was an independent predictor of rapid progression to cirrhosis.Conclusions:Our study confirmed recently published findings indicating that obesity maybe considered as a predictor of rapid disease progression in CHC patients.It suggests that weight reduction may play a significant role in hepatitis C management and constitute an alternative,especially among non-responders or patients with contraindications to interferon therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952